Precision Medicine Quarterly

Labcorp Acquires Personal Genome Diagnostics

2021-12-23T11:27:21-05:00December 23rd, 2021|

Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into a definitive agreement to acquire Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products. The addition of PGDx and its technology complements and accelerates Labcorp’s existing liquid [...]

GenXys Inks Deal with Precision Genetics for Personalized Medicine

2021-12-22T13:41:03-05:00December 22nd, 2021|

GenXys Healthcare Systems Inc. (GenXys) is adding a new value dimension to Precision Genetics and the personalized health marketplace. Precision prescribing has become a leading method to bring pharmacogenetics (PGx) closer to the standard of care for certain conditions that often carry a high cost and a lower rate of medication effectiveness. Precision Genetics [...]

Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn’s Proprietary Gene Traffic Control® Platform

2021-12-22T13:04:49-05:00December 22nd, 2021|

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), today announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform. The collaboration includes a co-development and co-commercialization agreement for Foghorn's selective BRM oncology program [...]

Lonza and Agilent Announce Strategic Collaboration to Integrate New Analytical Technologies with Lonza’s Cocoon Platform

2021-12-22T12:59:58-05:00December 22nd, 2021|

Lonza, a leading global cell and gene therapy manufacturer, and Agilent Technologies, a leader in life sciences analytics, diagnostics, and applied chemical markets, today announced a collaboration that has the potential to transform the way personalized cell therapies are manufactured and realized. Product quality and consistency are significant challenges for cell therapy manufacturing due [...]

Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401

2021-12-22T12:57:25-05:00December 22nd, 2021|

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb (NYSE: BMY), announced that they have entered into a license, development and commercialization agreement (the “agreement”) for Immatics’ TCR Bispecific candidate, IMA401. This press release features multimedia. View the full [...]

Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021

2021-12-22T12:55:02-05:00December 22nd, 2021|

Novartis recently announced the introduction of T-Charge™, the company’s next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. At the 63rd American Society of Hematology Annual Meeting & Exposition (ASH) 2021, Novartis will present early clinical data from ongoing Phase I clinical trials [...]

Oracle Buys Cerner

2021-12-22T12:50:16-05:00December 22nd, 2021|

Oracle Corporation (NYSE: ORCL) and Cerner Corporation have jointly announced an agreement for Oracle to acquire Cerner through an all-cash tender offer for $95.00 per share, or approximately $28.3 billion in equity value. Cerner is a leading provider of digital information systems used within hospitals and health systems to enable medical professionals to deliver [...]

Go to Top